Unlock All Angles.
Get Started
SubscribeLogin
Israel-Hamas Conflict
Donald Trump
Natural Disasters
Baseball
Social Media
WWE
Democratic Party
Republican Party
Pope Francis
White House
Artificial Intelligence
Cryptocurrency
US Crime
Published • loading... • Updated

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

Summary by Hastings Tribune
BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug…

1 Articles

All
Left
Center
1
Right
Hastings TribuneHastings Tribune
Center

Tempest Receives Orphan Drug Designation from the FDA for TPST-1495 to Treat Patients with FAP

BRISBANE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-class1 targeted and immune-mediated therapeutics to fight cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug…

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 100% of the sources are Center
100% Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Hastings Tribune broke the news in on Monday, April 21, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Brisbane

Brisbane

You have read out of your 5 free daily articles.

Join us as a member to unlock exclusive access to diverse content.

News
For You
SearchBlindspotLocal